ITLUCAS: Iraqi Trial for Lung Cancer Screening

Sponsor
Oncology Teaching Hospital, Baghdad (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04366661
Collaborator
(none)
500
1
1
46
10.9

Study Details

Study Description

Brief Summary

Lung cancer is a global problem. Worldwide, 1.2 million people die of lung cancer each year. In Iraq, lung cancer is the most common malignancy after breast cancer and the leading cause of cancer-related death. Tobacco smoking plays a major role in lung cancer; it is reported in 85-90% of lung cancer patients yet environmental tobacco smoke, environmental and domestic air pollution, work-related risk factors, radon exposure, and viruses may also have an impact on lung cancer incidence rates. Early detection of the disease before patients develop symptoms considers the best way to improve patient outcomes. IT LUCAS is designed to evaluate the utility of low-dose computed tomography (LDCT) screening in early detection and management of lung cancer in high-risk people.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: low dose CT
N/A

Detailed Description

Background Lung cancer is a global problem. Worldwide, 1.2 million people die of lung cancer each year. In Iraq, lung cancer is the most common malignancy after breast cancer and the leading cause of cancer-related death. Tobacco smoking plays a major role in lung cancer; it is reported in 85-90% of lung cancer patients yet environmental tobacco smoke, environmental and domestic air pollution, work-related risk factors, radon exposure, and viruses may also have an impact on lung cancer incidence rates. Early detection of the disease before patients develop symptoms considers the best way to improve patient outcomes. Screening for lung cancer using low dose computed tomography (LDCT) has been the subject of research studies since the 1990s. It has been reported to be superior to CXR and septum cytology for small tumors detection.

Aim of the study IT LUCAS is designed to evaluate the utility of LDCT screening in early detection and management of lung cancer in high-risk people in Iraq.

Study design 500 healthy participants aged 50-75 years with a history of smoking of at least 30 pack year of smoking were recruited from Ministries of Oil and Transport. They were offered Low dose CT of the chest. Nodules with suspicious (Lung RADs 4A or 4B) findings were classified as positive and referred to the Respiratory Department for further workup and biopsy. Nodules with Lung RADS 3 features are reviewed after 6 months while those with Lung RADS 2 offered a LDCT after 12 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Iraqi Trial for Lung Cancer Screening
Actual Study Start Date :
Jun 1, 2018
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: screening

Participants undergo low dose CT of the chest

Diagnostic Test: low dose CT
Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT

Outcome Measures

Primary Outcome Measures

  1. The efficacy of LD CT in lung cancer screening [2 years]

    The number of lung nodules with Lung RADS 4A, 4B and 4X, cancer predictive value and false-positive value

Secondary Outcome Measures

  1. noncancerous lung lesions [2 years]

    the number of nodules with Lung RADS 2 and 3 features

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • male or female

  • aged between 50 and 75

  • smokers or ex-smoker

  • tobacco exposure of more than 30 pack-years

Exclusion Criteria:
  • History of cancer within the last 5 years other than non-melanoma skin cancer or carcinoma in situ,

  • heart or respiratory severe co-morbidity with contraindications to thoracoscopy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oncology Teaching Hospital Baghdad Iraq

Sponsors and Collaborators

  • Oncology Teaching Hospital, Baghdad

Investigators

  • Principal Investigator: Enam A Khalil, Oncology Teaching Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Oncology Teaching Hospital, Baghdad
ClinicalTrials.gov Identifier:
NCT04366661
Other Study ID Numbers:
  • OTH267
First Posted:
Apr 29, 2020
Last Update Posted:
Mar 8, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Oncology Teaching Hospital, Baghdad
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2021